“…Human epidermal growth factor receptor 2 (HER2) abnormalities, including protein overexpression, gene amplification and mutation, play an important role in the carcinogenesis and development of many cancers, including urothelial cancer. Gene amplification or protein overexpression of HER2 occurs in 15%−20% of breast cancer cases, 1 10%−30% of gastric cancer cases, 20%−30% of ovarian cancer cases 2 and 8% of renal collecting duct carcinoma cases 3 ; it is associated with tumor progression and poor prognosis. In bladder carcinoma, HER2 overexpression is correlated with more aggressive behavior and poor outcome, with an overexpression [immunohistochemistry (IHC) 3+] rate of 12.4% (59/475).…”